TGFB1: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It's the GeneMedi's summary page for Target/Biomarker Introduction of TGFB1. The page also collects GeneMedi's different modalities and formats products for TGFB1 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the TGFB1 target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Transmembrane Protein.
This gene encodes a secreted ligand of the TGF-beta (transforming growth factor-beta) superfamily of proteins. Ligands of this family bind various TGF-beta receptors leading to recruitment and activation of SMAD family transcription factors that regulate gene expression. The encoded preproprotein is proteolytically processed to generate a latency-associated peptide (LAP) and a mature peptide, and is found in either a latent form composed of a mature peptide homodimer, a LAP homodimer, and a latent TGF-beta binding protein, or in an active form consisting solely of the mature peptide homodimer. The mature peptide may also form heterodimers with other TGFB family members. This encoded protein regulates cell proliferation, differentiation and growth, and can modulate expression and activation of other growth factors including interferon gamma and tumor necrosis factor alpha. This gene is frequently upregulated in tumor cells, and mutations in this gene result in Camurati-Engelmann disease. [provided by RefSeq, Aug 2016]
|Gene Official Name||TGFB1|
|Gene Alias||CED, DPD1, LAP, TGFB, TGFbeta|
|Protein Sub-location||Transmembrane Protein|
|Category||Therapeutics Target, INN Index, Cytokine Target, Immuno-oncology Target|
Pre-made TGFB1-specific INN-index biosimilar (antibody&conjugates)-Fresolimumab, dalutrafusp alfa, metelimumab
Anti-TGFB1 therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
|Cat No.||Products Name (INN Index)||INN Name||Previous Name||Target||Format||Order|
|GMP-Bios-ab-223||Pre-Made Fresolimumab biosimilar, Whole mAb, Anti-TGFB/TGFB1 Antibody: Anti-CED/DPD1/IBDIMDE/LAP therapeutic antibody||Fresolimumab||TGFB/TGFB1||Whole mAb|
|GMP-Bios-INN-793||Pre-Made Dalutrafusp Alfa P Alfaiosimilar, Bispecific, Anti-NT5E/CD73;TGFB1;TGFB3 Antibody: Anti-eN/NTE/eNT/CALJA;CED/DPD1/IBDIMDE/LAP/TGF-beta1/TGFbeta;ARVD/ARVD1/LDS5/RNHF therapeutic antibody||dalutrafusp alfa||NT5E/CD73;TGFB1;TGFB3||Bispecific|
|GMP-Bios-INN-908||Pre-Made Metelimumab Biosimilar, Whole Mab, Anti-Tgfb1 Antibody: Anti-CED/DPD1/IBDIMDE/LAP therapeutic antibody||metelimumab||TGFB1||Whole mAb|
Pre-made anti-TGFB1 inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark reference antibody for drug discovery and mechanism of action (MOA) research
Pre-made anti-TGFB1 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-TGFB1 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
|Cat No.||Antibody Name||Format||Classified by tag||Order|
|GM-Tg-hg-T97257-Ab||Anti-TGFB1 monoclonal antibody||mab||Biofunctional antibody, Therapeutics Target antibody, Cytokine antibody|